Plagiarism topples paper co-authored by top tamoxifen scientist
Expert Opinion on Pharmacotherapy has retracted a 2011 paper for plagiarism by two authors, one of whom, V. Craig Jordan, is a leading researcher on the class of drugs known as selective estrogen receptor modulators, or SERMs, and is credited with discovering the anti-tumor properties of the breast cancer drug tamoxifen.
The editor would like to inform the readers that the following article has been withdrawn due to duplication of previously published material:
- SS Ko, VC Jordan. Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. Expert Opin Pharmacother. 2011;12(4):657-674
An author of this article, VC Jordan, noticed that his co-author, SS Ko, included various sections and sentences in this paper that were copied from a number of previously published articles. This has also been confirmed by the editor.
We would like to apologise to the authors of the following papers and to our readers for inadvertently publishing replicated material from these papers, which is not condoned by the publishing and scientific community:
- Lee WL, Chao HT, Cheng MH, et al. Rational for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. The European Menopause Journal. 2008;60:92-107
- Vogel V, Constantino J, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. Cancer Prev Res. 2010;3(6):696-706
- Vogel. Tipping the Balance for the Primary Prevention of Breast Cancer. JNCI. 2010;102(22):1683-1685
- Riggs BL and Hartmann LC. Selective Estrogen-Receptor Modulators – Mechanisms of Action and Application to Clinical Practice. NEJM. 2003;348(7):618-629
- Visvanathan K, Chlebowski R, Hurley P, et al. American Society of Clinical Oncology Clinical Practice Guidline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. J Clin Oncol. 2009;27:3253-3258
- Gnant M. Can Oral Bisphosphonates Really Reduce the Risk of Breast Cancer in Healthy Women? J Clin Oncol. 2010;3548-3551
The retracted paper — which has only been cited by the the retraction itself, according to Thomson Scientific’s Web of Knowledge — is the only one we could find by Jordan and Ko, whose name does not appear on the Georgetown website. We have left a message for Jordan and will update this post if we hear from him.
Hat tip: Clare Francis